Cancer Immunotherapy

From immune modulation to immune programming

Current cancer therapies can target oncogenic pathways, release immune checkpoints or engage specific immune mechanisms.

RNA creates another possibility:

temporarily instructing cells to produce a biological function that complements an existing therapeutic strategy.

This function may be:

a tumor antigen,

an immune-stimulatory factor,

a synthetic receptor,

or another molecular program designed to reshape the interaction between tumor and immune system.

Because the instruction is transient, biological activity can be generated for a defined period of time and then allowed to decline.

Program the immune response without permanently rewriting the cell.

RNA-ONE for Cancer Immunotherapy

GEG Tech’s RNA-BEV platform for in vivo immune programming

RNA-ONE is GEG Tech’s proprietary RNA-BEV technology for transient delivery of functional RNA.

For cancer immunotherapy, the platform combines three properties:

Cargo. Tropism. Time.

One platform. Multiple immuno-oncology strategies.

Cancer immunotherapy is unlikely to depend on a single therapeutic mechanism.

RNA-ONE can support several complementary development strategies from the same underlying delivery platform.

Therapeutic cancer vaccination

RNA-ONE can be used to transiently express tumor-associated antigens or other immunogenic sequences as part of therapeutic vaccination strategies.

The platform can also support combinations in which antigen expression is accompanied by additional RNA-encoded immune signals.

This creates the possibility of programming not only what the immune system sees, but also aspects of how the immune response is shaped.

RNA-ONE’s existing preclinical vaccination programs provide a technological foundation for adapting this approach to cancer immunotherapy.

Combination with small molecules and antibodies

RNA delivery does not need to replace existing oncology treatments.

It can provide an additional biological layer.

Small molecules may inhibit or activate specific pathways.

Monoclonal antibodies may block checkpoints or engage immune mechanisms.

RNA-ONE can potentially complement these approaches by transiently introducing a biological function that is difficult to provide through conventional pharmacology alone.

This creates a modular combination strategy:

drug or antibody to modulate the existing biology,

RNA to transiently add a new biological instruction.

For combination oncology, the vector therefore becomes a way to connect pharmacological intervention with programmable biology.

Transient CAR expression

CAR therapies have demonstrated the power of genetically redirecting immune cells.

Most current approaches rely on ex vivo cell manipulation and persistent receptor expression.

RNA delivery opens another possibility:

transient expression of synthetic receptors directly in immune cells.

A transient CAR program could allow immune-cell function to be modified for a defined period without requiring permanent genetic modification.

This approach may be particularly relevant as the field moves toward increasingly direct in vivo cell engineering.

RNA-ONE provides a platform on which these strategies can be developed through cargo design and tropism engineering.

In vivo immune-cell engineering

Beyond CARs, RNA can encode a broad range of functions capable of modifying immune-cell behavior.

The objective may be to enhance activation, modify cell–cell interactions, alter trafficking or transiently introduce a new functional program.

This creates a broader concept:

the immune cell itself becomes a transiently programmable therapeutic system.

Direct in vivo programming could eventually reduce the dependence on complex ex vivo manufacturing and expand the range of patients and settings accessible to engineered-cell therapies.

Delivery is the key enabling step.

An in vivo foundation

RNA-ONE has already been evaluated through systemic administration in preclinical models.

These studies demonstrate that functional RNA can be delivered in vivo and provide information on biodistribution across different tissues.

In immune-related experimental settings, systemic RNA-ONE delivery has shown access to immune-relevant compartments, including the spleen, supporting its evaluation for direct immune programming.

At the same time, systemic biodistribution studies indicate limited accumulation in major filtering organs such as the liver.

These observations provide a practical basis for developing immune-targeted RNA-ONE strategies and for further refining cellular tropism through envelope engineering.

Designed to complement existing cancer therapies

One of the strengths of a programmable RNA platform is that it does not require the therapeutic strategy to be built around the vector.

RNA-ONE can instead be integrated into an existing oncology concept.

A partner may already have:

a validated cancer target,

a small-molecule inhibitor,

a therapeutic antibody,

a tumor antigen,

a synthetic receptor,

or an immune-modulatory hypothesis.

RNA-ONE provides a way to introduce an additional transient biological function around that existing asset.

This makes the platform particularly suited to combination development.

From platform capability to partner programs

RNA-ONE has already moved beyond the stage of demonstrating basic RNA delivery.

The platform has been:

validated for functional RNA expression,

evaluated following systemic administration,

characterized for preclinical biodistribution,

shown to reach immune-relevant biological compartments,

Technology maturity

A development platform for oncology partners

GEG Tech operates through a collaborative studio-lab model.

Cancer immunotherapy programs can start from a partner’s existing therapeutic asset or biological hypothesis.

Collaboration can include:

Bring the therapeutic strategy. We engineer the RNA layer around the immune objective.

Evidence & milestones

RNA-ONE development in immuno-oncology builds on several complementary areas of platform validation.

In vivo delivery milestone

Systemic RNA delivery to immune-relevant compartments

Preclinical systemic administration studies have demonstrated functional RNA delivery and access to immune-relevant tissues, including the spleen, providing a foundation for direct in vivo immune-programming strategies.

Platform milestone

Programmable antigen and immune-function delivery

RNA-ONE vaccination programs have established the platform’s ability to deliver transient biological instructions relevant to immune activation and antigen presentation.

Emerging programs

Transient immune-cell engineering

GEG Tech is extending RNA-ONE toward strategies involving synthetic-receptor expression and direct in vivo immune-cell programming.

Scientific evidence